Literature DB >> 9744511

Randomized study of chemotherapy and surgery versus radiotherapy for stage IIIA non-small-cell lung cancer: a National Cancer Institute of Canada Clinical Trials Group Study.

F A Shepherd1, M R Johnston, D Payne, R Burkes, J Deslauriers, Y Cormier, L D de Bedoya, J Ottaway, K James, B Zee.   

Abstract

Thirty-one patients with stage IIIA (N2) non-small-cell lung cancer were randomized to receive radiotherapy alone or chemotherapy with cisplatin and vinblastine followed by surgery. Response rates to induction chemotherapy and radiotherapy were 50% and 53.3% respectively. Complete surgical resection was possible for 62.5% of patients. Median survival times were 16.2 and 18.7 months for radiotherapy alone and chemotherapy-surgery respectively (P = Ns), with no long-term improvement in survival seen with combined-modality treatment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9744511      PMCID: PMC2063048          DOI: 10.1038/bjc.1998.560

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  4 in total

1.  Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer.

Authors:  W T Sause; C Scott; S Taylor; D Johnson; R Livingston; R Komaki; B Emami; W J Curran; R W Byhardt; A T Turrisi
Journal:  J Natl Cancer Inst       Date:  1995-02-01       Impact factor: 13.506

Review 2.  Induction chemotherapy for locally advanced non-small cell lung cancer.

Authors:  F A Shepherd
Journal:  Ann Thorac Surg       Date:  1993-06       Impact factor: 4.330

3.  A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

Authors:  R Rosell; J Gómez-Codina; C Camps; J Maestre; J Padille; A Cantó; J L Mate; S Li; J Roig; A Olazábal
Journal:  N Engl J Med       Date:  1994-01-20       Impact factor: 91.245

4.  Randomized trial of neoadjuvant therapy for lung cancer: interim analysis.

Authors:  H I Pass; H W Pogrebniak; S M Steinberg; J Mulshine; J Minna
Journal:  Ann Thorac Surg       Date:  1992-06       Impact factor: 4.330

  4 in total
  13 in total

Review 1.  Induction chemotherapy or chemoradiotherapy before surgery for non-small-cell lung cancer.

Authors:  K S Albain
Journal:  Curr Oncol Rep       Date:  2000-01       Impact factor: 5.075

Review 2.  Surgery for non-small cell lung cancer: systematic review and meta-analysis of randomised controlled trials.

Authors:  G Wright; R L Manser; G Byrnes; D Hart; D A Campbell
Journal:  Thorax       Date:  2006-01-31       Impact factor: 9.139

Review 3.  The role of induction therapy for resectable non-small cell lung cancer.

Authors:  Thomas E Stinchcombe; Mark A Socinski
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Effect of preoperative radiotherapy on overall survival in N2 non-small-cell lung cancer: a propensity score-matched analysis of Surveillance, Epidemiology, and End Results database.

Authors:  Yunan Wang; Yunliang Cao; Mengjia Wu; Yanyi Lu; Bo He; Lei Zhou; Wei Hu
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-06-15

5.  Non-small cell lung cancer: the challenges of the next decade.

Authors:  Thierry Le Chevalier
Journal:  Front Oncol       Date:  2011-09-30       Impact factor: 6.244

Review 6.  Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis.

Authors:  Ya-Ping Xu; Bo Li; Xiao-Ling Xu; Wei-Min Mao
Journal:  Medicine (Baltimore)       Date:  2015-06       Impact factor: 1.889

Review 7.  Definitive radiochemotherapy versus surgery within multimodality treatment in stage III non-small cell lung cancer (NSCLC) - a cumulative meta-analysis of the randomized evidence.

Authors:  Christoph Pöttgen; Wilfried Eberhardt; Georgios Stamatis; Martin Stuschke
Journal:  Oncotarget       Date:  2017-06-20

8.  Combined modality therapy in Stage IIIA non-small cell lung cancer: clarity or confusion despite the highest level of evidence?

Authors:  Branislav Jeremic; Francesc Casas; Pavol Dubinsky; Antonio Gomez-Caamano; Nikola Cihoric; Gregory Videtic; Miroslav Latinovic
Journal:  J Radiat Res       Date:  2017-05-01       Impact factor: 2.724

9.  Risks and Benefits of Multimodal Esophageal Cancer Treatments: A Meta-Analysis.

Authors:  Lei Sun; Fen Zhao; Yan Zeng; Cheng Yi
Journal:  Med Sci Monit       Date:  2017-02-19

10.  Neoadjuvant chemoradiotherapy or chemotherapy followed by surgery is superior to that followed by definitive chemoradiation or radiotherapy in stage IIIA (N2) nonsmall-cell lung cancer: a meta-analysis and system review.

Authors:  Xiao-Ling Xu; Li Dan; Wei Chen; Shuang-Mei Zhu; Wei-Min Mao
Journal:  Onco Targets Ther       Date:  2016-02-22       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.